Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SAN ANTONIO – bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), currently trading at $0.47 with a market capitalization of $8.4 million, has announced significant improvements to its CyPath® Lung test, aimed at early-stage lung cancer detection. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, though investors should note its high volatility with a beta of 3.47. These enhancements, unveiled earlier this week, are expected to halve the time needed for sample data acquisition and reduce sample processing costs by around 60%. These operational improvements come at a crucial time, as InvestingPro data shows the company’s revenue growth forecast for FY2025 indicates a 35% decline, highlighting the importance of cost optimization initiatives.
The company, which specializes in noninvasive diagnostic tests, has optimized lab workflows and data acquisition processes, achieving these efficiencies without altering the test or its collection and analysis methods. These changes are anticipated to increase overall throughput by over 10% and cut unit costs by more than 25%.
According to Maria Zannes, President and CEO of bioAffinity Technologies, these developments stem from a year-long operational analysis aimed at improving CyPath® Lung while maintaining its high performance standards. The test employs flow cytometry and artificial intelligence to analyze patient sputum samples for malignant cell populations. Clinical trials have shown CyPath® Lung to have 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in high-risk patients with small lung nodules.
Zannes also referenced an economic impact study demonstrating potential healthcare savings with the adoption of CyPath® Lung. The study indicated that Medicare patients with positive lung cancer screenings could have saved an average of $2,773 per patient in 2022, totaling $379 million. For privately insured patients, the savings could have been $6,460 per patient, or nearly $895 million nationwide.
The economic benefits are attributed to fewer follow-up assessments, procedures, and related complications when CyPath® Lung is included in the standard care regimen. While the company shows promise in cost savings, InvestingPro analysis reveals challenges with a current ratio of 0.87 and negative EBITDA of -$8.35 million in the last twelve months. For deeper insights into bioAffinity’s financial health and 12 additional ProTips, consider exploring InvestingPro’s comprehensive analysis tools.
bioAffinity Technologies focuses on the development of noninvasive tests for early cancer detection and broad-spectrum cancer treatments. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. The company achieved impressive revenue growth of 270% in the last twelve months, though maintaining this momentum remains crucial for long-term sustainability.
The information in this article is based on a press release statement from bioAffinity Technologies, Inc. and does not include any forward-looking statements or implied predictions.
In other recent news, bioAffinity Technologies, Inc. reported a 270% increase in revenue for 2024, reaching $9.4 million, largely due to the expanded demand for its CyPath® Lung test, now covered by Medicare. However, the company anticipates a decrease in revenue for 2025, projecting between $6 million to $8 million, as it discontinues certain unprofitable services to focus on cost reductions. The company also announced strategic cost-saving measures aimed at boosting CyPath® Lung sales, expecting to save approximately $4 million annually by reducing workforce and improving operational efficiency. Meanwhile, bioAffinity has secured a patent in Australia for its CyPath® Lung test, which will enhance its intellectual property portfolio. The patent is expected to be granted automatically in three months and will remain in force until 2042, barring any opposition. Additionally, the company received a notice from Nasdaq for not meeting the minimum bid price requirement, although it has until August 6, 2025, to regain compliance. Despite these challenges, bioAffinity continues to focus on expanding its market reach and enhancing its financial performance. The company raised $1.4 million through warrant exercises in February 2025 to support its ongoing operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.